tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Naureen Quibria, 12 are a BUY (92.31%), 1 are a HOLD (7.69%).
Analyst Naureen Quibria, currently employed at CAPITAL ONE, carries an average stock price target met ratio of 7.14% that have a potential upside of 31.8% achieved within 130 days.
Naureen Quibria’s has documented 25 price targets and ratings displayed on 7 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on IMMP, Immutep Ltd ADR at 17-May-2024.
Analyst best performing recommendations are on CMRX (CHIMERIX).
The best stock recommendation documented was for CMRX (CHIMERIX) at 9/7/2022. The price target of $7 was fulfilled within 910 days with a profit of $4.83 (222.58%) receiving and performance score of 2.45.
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 28-Feb-2025
$10
19 days ago
(28-Jan-2026)
0/2 (0%)
$7.56 (309.84%)
Buy Since 22-Oct-2020
$10
$8.4 (525.00%)
$13
6 months 10 days ago
(06-Aug-2025)
0/6 (0%)
$7.56 (309.84%)
Buy Since 08-Oct-2020
$10
$8.4 (525.00%)
$7
1 years 2 months 3 days ago
(13-Dec-2024)
1/6 (16.67%)
$6.08 (155.10%)
547
Buy Since 07-Dec-2021
$5
$3.4 (212.50%)
$6
3 years 4 months 20 days ago
(27-Sep-2022)
1/3 (33.33%)
$3.45 (222.58%)
533
Buy Since 09-Aug-2021
$25
$23.4 (1462.50%)
$20
4 years 5 months 7 days ago
(09-Sep-2021)
0/2 (0%)
$18.01 (257.65%)
What Year was the first public recommendation made by Naureen Quibria?
